The US FDA approved Vertex Pharmaceuticals’ Journavx, a new pain pill designed to reduce addiction and overdose risks associated with opioids, offering an alternative for short-term pain relief post-surgery or injuries. The drug, priced at $15.50 per pill, works by blocking pain-signaling proteins rather than targeting brain receptors like opioids, showing promise despite modest effectiveness and some side effects. While Vertex faces challenges with its chronic pain drug pipeline, they plan to proceed with further studies to potentially address the opioid crisis.
Full Article
Federal housing agency refers NY Attorney General James to DOJ for investigation
The Federal Housing Finance Agency (FHFA) has referred New York Attorney General Letitia James to the Justice Department over allegations related to a loan for her Virginia property. FHFA Director William Pulte claims that James misrepresented her principal residence status, suggesting potential violations of criminal laws, including fraud, to secure favorable loan terms. In response, James' office emphasized her commitment to protecting New Yorkers and stated she would not be intimidated, highlighting her ongoing legal...
Read more